Format

Send to

Choose Destination
See comment in PubMed Commons below
Mol Cell Biochem. 2017 Mar;427(1-2):177-185. doi: 10.1007/s11010-016-2909-5. Epub 2016 Dec 30.

Alternative new mesenchymal stem cell source exerts tumor tropism through ALCAM and N-cadherin via regulation of microRNA-192 and -218.

Author information

1
Department of Biology Education, College of Education, Pusan National University, Pusan, 609-735, South Korea.
2
Institute of Catholic Integrative Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, College of Medicine, Incheon, 403-720, South Korea.
3
Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, 120-752, South Korea.
4
Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, 94305, USA.
5
Department of Pharmacology, Yale University School of Medicine, New Haven, CT, 06520, USA.
6
Department of Molecular Physiology, College of Pharmacy, Kyungpook National University, Daegu, 702-701, South Korea.
7
Department of Life Systems, Sookmyung Women's University, 52 Hyochangwon-gil, Seoul, 140-742, South Korea.
8
Institute for Bio-Medical Convergence, College of Medicine, Catholic Kwandong University, Gangwon-do, 210-701, South Korea.
9
Catholic Kwandong University International, St. Mary's Hospital, Incheon, 404-834, South Korea.
10
Institute of Catholic Integrative Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, College of Medicine, Incheon, 403-720, South Korea. mls1004@catholic.ac.kr.
11
Department of Biology Education, College of Education, Pusan National University, Pusan, 609-735, South Korea. wchang1975@pusan.ac.kr.

Abstract

Gliomas are the most common type of malignant primary brain tumors. Some treatments of gliomas exist, but they are rarely curative. Mesenchymal stem cells (MSCs) are emerging as potential modes of targeted cancer therapy owing to their capacity for homing toward tumor sites. It has been proposed that MSCs derived from various sources, such as bone marrow, adipose tissue and umbilical cord blood, can be used as cell-based therapy for brain tumors. Here, MSCs obtained from the synovial fluid of osteoarthritis or rheumatoid arthritis patients were investigated as therapeutic candidates. Specifically, we compared migratory and adhesive abilities, as well as expression levels of related genes and microRNA in bone marrow derived-MSCs (BMMSCs), adipose derived-MSCs (ADMSCs), and synovial fluid derived-MSCs (SFMSCs) after treatment with conditioned medium from gliomas. Migration and adhesion of SFMSCs increased through upregulation of the activated lymphocyte cell adhesion molecule (ALCAM) and N-cadherin by microRNA-192 and -218 downregulation, similar to BMMSCs and ADMSCs. Migratory capacities of all types of MSCs were evaluated in vivo, and SFMSCs migrated intensively toward gliomas. These results suggest that SFMSCs have potential for use in cell-based antitumor therapies.

KEYWORDS:

Activated lymphocyte cell adhesion molecule; N-Cadherin; Synovial fluid derived-mesenchymal stem cells; Tumor tropism; microRNA-192; microRNA-218

PMID:
28039611
PMCID:
PMC5306073
DOI:
10.1007/s11010-016-2909-5
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Support Center